Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11798096 | 0.93 | NR1H2 (0.50) | S1PR1NR1H2TSHRGLAGAA | |
| SCHEMBL26460616 | 0.90 | GAA (0.55) | S1PR1NR1H2TSHRGLAGAA | |
| SCHEMBL11802082 | 0.86 | NR1H2 (0.53) | S1PR1NR1H2TSHRGLAGAA | |
| SCHEMBL2797579 | 0.83 | GAA (0.48) | S1PR1NR1H2TSHRGLAGAA | |
| SCHEMBL2795028 | 0.82 | GAA (0.47) | S1PR1NR1H2TSHRGLAGAA | |
| SCHEMBL2795017 | 0.81 | GAA (0.50) | S1PR1NR1H2TSHRGLAGAA | |
| SCHEMBL18085142 | 0.81 | S1PR1 (0.47) | S1PR1TSHRTYRCYP3A4MAPT | |
| SCHEMBL5111216 | 0.79 | NR1H2 (0.47) | NR1H2TSHRGLAGAAPOLB | |
| SCHEMBL282158 | 0.79 | NR1H2 (0.55) | NR1H2TSHRGLAGAAPOLB | |
| SCHEMBL22731335 | 0.78 | S1PR1 (0.46) | S1PR1TSHRTYRCYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183263-B2 | Heteroaryl substituted thiazoles | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183263-B2 | Heteroaryl substituted thiazoles | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8106209-B2 | Substituted aminothiazole prodrugs of compounds with anti-HCV activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106209-B2 | Substituted aminothiazole prodrugs of compounds with anti-HCV activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| EP-2297143-A1 | SUBSTITUTED AMINOTHIAZOLE PRODRUGS OF COMPOUNDS WITH ANTI-HCV ACTIVITY | Achillion Pharmaceuticals, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009149436-A1 | SUBSTITUTED AMINOTHIAZOLE PRODRUGS OF COMPOUNDS WITH ANTI-HCV ACTIVITY | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| US-20090304605-A1 | Substituted Aminothiazole Prodrugs of Compounds with Anti-HCV Activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090304605-A1 | Substituted Aminothiazole Prodrugs of Compounds with Anti-HCV Activity | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090041720-A1 | HETEROARYL SUBSTITUTED THIAZOLES | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| US-20090041720-A1 | HETEROARYL SUBSTITUTED THIAZOLES | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2008147557-A2 | HETEROARYL SUBSTITUTED THIAZOLES AND THEIR USE AS ANTIVIRAL AGENTS | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090304605-A1 | Substituted Aminothiazole Prodrugs of Compounds with Anti-HCV Activity | BCAT1, CCNT1, EIF2AK2 | S1PR1 3081/4885NR1H2 1538/4885TSHR 3235/4885 |
| US-20090041720-A1 | HETEROARYL SUBSTITUTED THIAZOLES | CYP3A43, CYP3A7, HAVCR2 | S1PR1 3564/4885NR1H2 329/4885TSHR 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.